Pertussis, Whooping Cough
Conditions
Keywords
Pertussis, Colonization, Vaccine, Immune response, BPZE1, Infection, Bordetella pertussis, B. pertussis, respiratory Tract Infection
Brief summary
This study evaluates the safety and immunogenicity of a higher dose formulation of a new live attenuated vaccine, BPZE1, intended to prevent Bordetella pertussis nasopharyngeal colonization and pertussis disease, and investigates whether higher doses of BPZE1 induce the live vaccine to colonize subjects' nasopharynx. The study is a Phase Ib (high dose), single centre, dose-escalating, placebo-controlled study of the live attenuated B. pertussis strain BPZE1 given as a single intranasal dose to healthy adult volunteer.
Interventions
BIOLOGICALBPZE1
Intranasal live, attenuated vaccine
OTHERPlacebo
Diluent
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 32 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy individual between 18 and 32 years of age, vaccinated or unvaccinated with acellular pertussis vaccine. 2. Female subject of child bearing potential must be willing to ensure that they use a highly efficient method of contraception during the study (e.g. contraceptive pill, intrauterine contraceptive device). 3. Informed consent form (ICF) signed by the subject. 4. Subject shall be able to attend all scheduled visits and to understand and comply with the study procedures.
Exclusion criteria
1. Individual with PT and/or PRN serum IgG antibodies ≥20 International units/ml (IU/ml). NOTE! One control group with PRN serum IgG antibodies ≥ 20 IU/ml will be included. 2. Vaccinated with the study vaccine in the Child Innovac study (EudraCT number 2010-019936-11). 3. Pregnant or lactating women. Pregnancy not planned and to be avoided during the study by use of effective contraceptive methods. 4. Blood pressure after resting ≥ 150/90 mm Hg at screening. 5. Heart rate after resting ≥ 80 bpm at screening. 6. Respiratory rate after resting ≥ 20/minute at screening. 7. Unwillingness to refrain from the use of nicotine products from screening through day 28. 8. Use of narcotic drugs and/or a history of drug/alcohol abuse with in the past 2 years prior to screening 9. The subject has donated blood or suffered from blood loss of at least 450 ml (1 unit of blood) within 60 days prior to screening or donated plasma within 14 days prior to screening. 10. Receipt of immunoglobulin, blood derived products, systemic corticosteroids or other immunosuppressant drugs within 90 days prior to day 0. 11. Asthma or other chronic respiratory problems. 12. Use of corticosteroids in the respiratory tract (e.g. nasal steroids, inhaled steroids) with in 30 days prior to day 0. 13. Receipt of a vaccine within the last 30 days prior to day 0 or planned vaccination with in the next 30 days after day 0. 14. Known hypersensitivity to any component of the study vaccine. 15. Current participation in any other clinical trial or participation (and during the whole study) in any clinical trial in the previous 3 months prior to day 0. 16. Inability to adhere to the protocol, including plans to move from the area. 17. Family (first degree) history of congenital or hereditary immunodeficiency. 18. Past or present infection with HIV, hepatitis B or C. 19. Chronic conditions requiring ongoing active medical interventions, such as diabetes mellitus or cardiovascular disease. 20. Any autoimmune or immunodeficiency disease/condition (inherited or iatrogenic). 21. Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or might affect the safety of the individual, e.g. evolving encephalopathy not attributable to another identifiable cause within 7 days of administration of a previous dose of any vaccine, hospitalization due to major depression or history of suicidal attempt. 22. Abnormal laboratory values outside the limit of normal values for the screening laboratory with clinical significance at the discretion of the investigator. 23. Person in frequent contact with children less than 1 year of age (parent, childcare worker, nurse, etc) or residence in the same household as persons with known immunodeficiency including persons on immunosuppressant therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | 28 days | Percentage is based on subjects experiencing at least one of the following events: * Cough and spasmodic cough of grade 2 or higher * Other respiratory tract AE related or possibly related to vaccination of grade 3 or higher * Any other AE related or possibly related to vaccination of grade 3 or higher |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Subjects With BPZE1 Colonization | 28 days | To assess the proportion of subjects having positive colonization of the human respiratory tract by live attenuated B. pertussis strain BPZE1 per group at any time period measured at 4, 7, 11, 14, 21 and 28 days post vaccination. |
| The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | 6 months | To assess the number of immune responders and levels of Immunoglobulin G/Immunoglobulin A (IgG/IgA) antibodies to pertussis toxin (PT), filamentous haemagglutinin adhesin (FHA), Pertactin (PRN), and fimbriae 2/3 in serum and nasopharyngeal aspirate. A positive antibody response after vaccination is defined as at least 100% increase from pre- to post-vaccination, to at least 4 times minimum level of detection (MLD) for PT, FHA, PRN, and fimbriae 2/3 in the post-vaccination sample. The 4 antigens described are the standard 4 antigens historically used to describe a serum immunological response to B. pertussis. The absolute serum antibody titers have not shown a correlation of protection in previous pertussis vaccine studies of the current acellular vaccine and there is no known serum antigen threshold of protection for pertussis. Antibodies are measured before vaccination and at 4, 7, 11, 14, 21, 28 days, 6-months and 12-months post-vaccination. |
Countries
Sweden
Contacts
PRINCIPAL_INVESTIGATORNabil Al-Tawil, MD, PhD
Karolinska University Hospital
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Individuals will be vaccinated once intranasally with the designated dose of Placebo at a Dose 2 x 0.4 mL (0.4 mL per nostril).
Placebo: Diluent | 12 |
| BPZE1 - 10,000,000 Cfu Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
BPZE1: Intranasal live, attenuated vaccine | 12 |
| BPZE1 - 100,000,000 Cfu Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
BPZE1: Intranasal live, attenuated vaccine | 12 |
| BPZE1 - 1,000,000,000 Cfu Individuals will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
BPZE1: Intranasal live, attenuated vaccine | 12 |
| BPZE1 - High Antibody 1,000,000,000 Cfu Individuals with high baseline antibodies will be vaccinated once intranasally with the designated dose of BPZE1 at a Dose 2 x 0.4 mL (0.4 mL per nostril).
BPZE1: Intranasal live, attenuated vaccine | 6 |
| Total | 54 |
Baseline characteristics
| Characteristic | Placebo | BPZE1 - 10,000,000 Cfu | BPZE1 - 100,000,000 Cfu | BPZE1 - 1,000,000,000 Cfu | BPZE1 - High Antibody 1,000,000,000 Cfu | Total |
|---|---|---|---|---|---|---|
| Age, Customized 20-25 years | 3 Participants | 2 Participants | 4 Participants | 3 Participants | 2 Participants | 14 Participants |
| Age, Customized <20 years | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| Age, Customized 25-30 years | 7 Participants | 7 Participants | 7 Participants | 6 Participants | 4 Participants | 31 Participants |
| Age, Customized >=30 years | 0 Participants | 3 Participants | 1 Participants | 3 Participants | 0 Participants | 7 Participants |
| BMI | 22 kg/m^2 | 22 kg/m^2 | 22 kg/m^2 | 23 kg/m^2 | 22 kg/m^2 | 22 kg/m^2 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants | 12 Participants | 12 Participants | 12 Participants | 6 Participants | 54 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Height | 1.74 m | 1.77 m | 1.8 m | 1.72 m | 1.76 m | 1.76 m |
| Oral Temperature | 36.5 C | 36.8 C | 36.6 C | 36.6 C | 36.3 C | 36.6 C |
| Region of Enrollment Sweden | 12 participants | 12 participants | 12 participants | 12 participants | 6 participants | 54 participants |
| Sex: Female, Male Female | 6 Participants | 5 Participants | 2 Participants | 7 Participants | 1 Participants | 21 Participants |
| Sex: Female, Male Male | 6 Participants | 7 Participants | 10 Participants | 5 Participants | 5 Participants | 33 Participants |
| Weight | 69 kg | 71 kg | 74 kg | 69 kg | 69 kg | 70 kg |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 12 | 0 / 6 |
| other Total, other adverse events | 11 / 12 | 11 / 12 | 11 / 12 | 9 / 12 | 5 / 6 |
| serious Total, serious adverse events | 0 / 12 | 1 / 12 | 1 / 12 | 0 / 12 | 0 / 6 |
Outcome results
Primary
The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28
Percentage is based on subjects experiencing at least one of the following events: * Cough and spasmodic cough of grade 2 or higher * Other respiratory tract AE related or possibly related to vaccination of grade 3 or higher * Any other AE related or possibly related to vaccination of grade 3 or higher
Time frame: 28 days
Population: Arms (Placebo separated from randomized groups)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Cough or Spasmodic Cough of grade >=2 | 1 Participants |
| Placebo | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other AE grade >=3 | 0 Participants |
| Placebo | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other respiratory tract AE of grade >=3 | 0 Participants |
| Low Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other respiratory tract AE of grade >=3 | 0 Participants |
| Low Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Cough or Spasmodic Cough of grade >=2 | 1 Participants |
| Low Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other AE grade >=3 | 0 Participants |
| Medium Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other respiratory tract AE of grade >=3 | 1 Participants |
| Medium Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Cough or Spasmodic Cough of grade >=2 | 1 Participants |
| Medium Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other AE grade >=3 | 0 Participants |
| High Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Cough or Spasmodic Cough of grade >=2 | 2 Participants |
| High Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other AE grade >=3 | 0 Participants |
| High Dose Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other respiratory tract AE of grade >=3 | 1 Participants |
| PRN High Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other respiratory tract AE of grade >=3 | 0 Participants |
| PRN High Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Cough or Spasmodic Cough of grade >=2 | 0 Participants |
| PRN High Group | The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events Between Day 0 and Day 28 | Other AE grade >=3 | 0 Participants |
Secondary
Proportion of Subjects With BPZE1 Colonization
To assess the proportion of subjects having positive colonization of the human respiratory tract by live attenuated B. pertussis strain BPZE1 per group at any time period measured at 4, 7, 11, 14, 21 and 28 days post vaccination.
Time frame: 28 days
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Proportion of Subjects With BPZE1 Colonization | Colonized | 0 Participants |
| Placebo | Proportion of Subjects With BPZE1 Colonization | Not Colonized | 12 Participants |
| Low Dose Group | Proportion of Subjects With BPZE1 Colonization | Not Colonized | 2 Participants |
| Low Dose Group | Proportion of Subjects With BPZE1 Colonization | Colonized | 10 Participants |
| Medium Dose Group | Proportion of Subjects With BPZE1 Colonization | Colonized | 9 Participants |
| Medium Dose Group | Proportion of Subjects With BPZE1 Colonization | Not Colonized | 3 Participants |
| High Dose Group | Proportion of Subjects With BPZE1 Colonization | Colonized | 10 Participants |
| High Dose Group | Proportion of Subjects With BPZE1 Colonization | Not Colonized | 2 Participants |
| PRN High Group | Proportion of Subjects With BPZE1 Colonization | Not Colonized | 4 Participants |
| PRN High Group | Proportion of Subjects With BPZE1 Colonization | Colonized | 2 Participants |
Secondary
The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination
To assess the number of immune responders and levels of Immunoglobulin G/Immunoglobulin A (IgG/IgA) antibodies to pertussis toxin (PT), filamentous haemagglutinin adhesin (FHA), Pertactin (PRN), and fimbriae 2/3 in serum and nasopharyngeal aspirate. A positive antibody response after vaccination is defined as at least 100% increase from pre- to post-vaccination, to at least 4 times minimum level of detection (MLD) for PT, FHA, PRN, and fimbriae 2/3 in the post-vaccination sample. The 4 antigens described are the standard 4 antigens historically used to describe a serum immunological response to B. pertussis. The absolute serum antibody titers have not shown a correlation of protection in previous pertussis vaccine studies of the current acellular vaccine and there is no known serum antigen threshold of protection for pertussis. Antibodies are measured before vaccination and at 4, 7, 11, 14, 21, 28 days, 6-months and 12-months post-vaccination.
Time frame: 6 months
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 1 Antigen | 2 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 4 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 2 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 3 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 3 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 2 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | Non-responding Subjects | 11 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 2 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 3 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 1 Antigen | 2 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 4 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 4 Antigens | 0 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | Non-responding Subjects | 10 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | Non-responding Subjects | 10 Participants |
| Placebo | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 1 Antigen | 1 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 4 Antigens | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 1 Antigen | 1 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 1 Antigen | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 4 Antigens | 2 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 3 Antigens | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 3 Antigens | 4 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 2 Antigens | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 4 Antigens | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | Non-responding Subjects | 1 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 3 Antigens | 4 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 1 Antigen | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | Non-responding Subjects | 1 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 2 Antigens | 1 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | Non-responding Subjects | 3 Participants |
| Low Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 2 Antigens | 1 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 2 Antigens | 1 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | Non-responding Subjects | 4 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 1 Antigen | 2 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 2 Antigens | 2 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 3 Antigens | 2 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 4 Antigens | 2 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | Non-responding Subjects | 5 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 1 Antigen | 2 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 3 Antigens | 4 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 4 Antigens | 0 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | Non-responding Subjects | 3 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 1 Antigen | 2 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 2 Antigens | 0 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 3 Antigens | 4 Participants |
| Medium Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 4 Antigens | 3 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 4 Antigens | 1 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 2 Antigens | 3 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 4 Antigens | 0 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 2 Antigens | 4 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 3 Antigens | 3 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | Non-responding Subjects | 1 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 1 Antigen | 4 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 4 Antigens | 3 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 2 Antigens | 6 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 1 Antigen | 1 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | Non-responding Subjects | 2 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | Non-responding Subjects | 0 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 3 Antigens | 4 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 3 Antigens | 3 Participants |
| High Dose Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 1 Antigen | 1 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 3 Antigens | 1 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | Non-responding Subjects | 2 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 3 Antigens | 2 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 4 Antigens | 0 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 4 Antigens | 0 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | Non-responding Subjects | 2 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | Non-responding Subjects | 2 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 3 Antigens | 1 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 1 Antigen | 0 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 2 Antigens | 2 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 4 Antigens | 1 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG or IgA Response | 2 Antigens | 1 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgG Response | 1 Antigen | 1 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 2 Antigens | 2 Participants |
| PRN High Group | The Proportion of Subjects That Have an Antibody Response to BPZE1 Vaccination | IgA Response | 1 Antigen | 1 Participants |